ABOUT MEDICUREMedicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.Medicure's core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT. Acquired in 2006, AGGRASTAT is experiencing renewe…
ABOUT MEDICURE Medicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure's core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT. Acquired in 2006, AGGRASTAT is experiencing renewed interest from hospitals and clinicians in the US due to its compelling clinical and economic evidence. The Company has an experienced commercial team dedicated exclusively to the marketing of AGGRASTAT. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty (PTCA) or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction (MI), or refractory ischemia/repeat cardiac procedure. For additional information and full Prescribing Information, health care professionals can visit the AGGRASTAT product website. The US rights to Aggrastat are owned by Medicure's subsidiary, Medicure International, Inc. (Barbados) and the product is distributed in the United States by Medicure's US subsidiary, Medicure Pharma, Inc. Medicure opportunistically looks at small molecule development opportunities and currently has development programs in the neurology and cardiology fields.
Team (1)
Sectors Medicure Inc. (TSXV:MPH) serves:
Life Sciences
Join Axial's Private M&A Platform
Medicure Inc. (TSXV:MPH) connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
